| Investment Objective The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equities and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved. |
|||||||||||||
| Inception Date |
28th June, 1999 | ||||||||||||
| Fund Manager |
Mr. V Srivatsa - B.Com., ACA, CWA, PGDM (IIM-I) Managing the scheme since Mar-2017 |
||||||||||||
| Fund AUM |
Fund size monthly average : 863.55 Crore Closing AUM : 827.96 Crore |
||||||||||||
| High/Low NAV in the month |
High Growth Option : 173.6246 Low Growth Option : 161.8430 |
||||||||||||
Total expense ratio (%) |
Regular : 2.31 Direct : 1.25 |
||||||||||||
Minimum Investment Amount |
Growth, IDCW: 5,000/- | ||||||||||||
Plans/Options
(Regular / Direct) |
Growth option IDCW option with Payout and Reinvestment | ||||||||||||
| No. of Unit Holding Accounts | 52,428 | ||||||||||||
| Market Capitalisation (%) |
|
||||||||||||
Load Structure |
Entry Load : Nil Exit Load : < 30 days – 1%;≥ 30 days – Nil |
||||||||||||
NAV per unit as on 31st October, 2021 |
Regular Growth Option 162.9783 Regular IDCW Option 125.9595 Direct Growth Option 176.7825 Direct IDCW Option 136.6411 |
||||||||||||
Benchmark Index |
S&P BSE Healthcare | ||||||||||||
SIP/SWP/STRIP |
 |
||||||||||||
| Fund Size | 863.55 Crore (Monthly Average as on 31/10/2021) | ||||||||||||
Overweight (Top 5) |
% of Nav |
Underweight (Top 5) |
% of Nav |
| Eris Lifesciences Ltd | 4.13 |
Sun Pharmaceuticals Industries Ltd. | -4.45 |
| Aurobindo Pharma Ltd. | 3.64 |
Divis Laboratories Ltd. | -4.09 |
| Ajanta Pharma Ltd. | 3.28 |
Apollo Hospitals Enterprise Ltd. | -3.50 |
| FDC Ltd. | 2.88 |
Laurus Labs Ltd. | -2.51 |
| Fortis Healthcare Ltd. | 2.56 |
Dr. Lal Pathlabs Ltd. | -1.91 |
UTI Healthcare Fund (Formerly known as UTI Pharma & Healthcare Fund) IDCW Declared |
||||||
Year |
IDCW |
Per unt |
NAV (Cum Div ) |
Face Value (per unit) |
NAV Date |
Record Date |
2006 |
25% |
2.50 |
21.34 |
10.00 |
10-01-2006 |
17-01-2006 |
2008 |
15% |
1.50 |
20.91 |
10.00 |
26-08-2008 |
02-09-2008 |
2010 |
17% |
1.70 |
32.65 |
10.00 |
28-10-2010 |
04-11-2010 |
The scheme IDCW details under regular plan.
Disclaimer:Pursuant to payment of Dividend/Bonus, the Nav of the income distribution cum capital withdrawal options of the schemes would fall to the extent of payout and statutory levy (if applicable)
|
Equity
|
% of NAV
|
Dr Reddy's Laboratories Ltd. |
10.01 |
Sun Pharmaceuticals Industries Ltd. |
8.86 |
Cipla Ltd. |
7.95 |
Aurobindo Pharma Ltd. |
6.65 |
Divis Laboratories Ltd. |
6.10 |
Fortis Healthcare Ltd. |
4.54 |
Lupin Ltd. |
4.50 |
Eris Lifesciences Ltd |
4.49 |
Ajanta Pharma Ltd |
4.11 |
IPCA Laboratories Ltd. |
3.26 |
Apollo Hospitals Enterprise Ltd. |
3.16 |
FDC Ltd. |
3.14 |
J.B.Chemicals & Pharmaceuticals Ltd |
2.77 |
Alembic Pharmaceuticals Ltd. |
2.64 |
Krishna Institute Of Medical Science Ltd |
2.63 |
Narayana Hrudayalaya Ltd |
2.61 |
Cadila Healthcare Ltd. |
2.54 |
Advanced Enzyme Technologies Ltd |
2.03 |
Alkem Laboratories Ltd |
1.98 |
Metropolis Healthcare Ltd |
1.02 |
Poly Medicure Ltd. |
1.61 |
AMI Organics Ltd |
1.57 |
Torrent Pharmaceuticals Ltd. |
1.48 |
Abbott India Ltd. |
1.46 |
Suven Pharmaceuticals Ltd |
1.36 |
Gland Pharma Ltd |
1.32 |
Proctor & Gamble Health Ltd |
1.28 |
Biocon Ltd. |
1.16 |
Windlas Biotec Ltd |
0.90 |
Laurus Labs Ltd. |
0.63 |
Net Current Assets |
2.24 |
TOTAL |
100.00 |
% of top 10 stocks |
60.47 |
Median Market Cap ( Cr) |
40,192 |
Weighted Average Market Cap |
56,240 |
Number of Securities |
30 |
All figures given are provisional and unaudited. |
Quantitative Indicators |
Fund |
Benchmark |
Beta |
0.89 |
1 |
Standard Deviation (Annual) |
17.98% |
19.73% |
Sharpe ratio |
1.13% |
|
| Portfolio Turnover Ratio (Annual) | 0.48 |
|
| P/B | 6.17 |
7.45 |
| P/E | 38.12 |
44.85 |
| RoE | 16.47 |
15.99 |
| Fund Performance Vs Benchmark (CAGR) as on 31st October, 2021 Growth of 10000 |
||||||
| Period | NAV Growth (%) |
S&P BSE Healthcare (%) |
Nifty 50 (%) |
NAV Growth () |
S&P BSE Healthcare () |
Nifty 50 () |
| 1 Year | 27.98 |
30.74 |
53.54 |
12,798 |
13,074 |
15,354 |
| 3 Years | 23.69 |
20.14 |
20.77 |
18,935 |
17,349 |
17,624 |
| 5 Years | 11.49 |
9.43 |
16.85 |
17,231 |
15,696 |
21,794 |
| Since inception* | 14.72 |
14.93 |
NA |
215,509 |
224,504 |
NA |
Different plans have a different expense structure. The performance details provided herein are of regular plan.
*Compounded annualized Growth Rate.
For performance details of other Schemes managed by the Fund Manager, please refer the respective Scheme sheets as listed Please click here in ‘Fund Manager Summary’. N.A Not
Available. No of Schemes Managed by Mr. V Srivatsa is 7.
As TRI data is not available since inception of the scheme, benchmark performance is calculated using composite CAGR of Nifty Pharma. PRI values from 28th June 1999 to 3rd
April 2006. TRI Value From 4th April 2006.
The performance of the benchmark is calculated using total return index variant of the benchmark index.
| Period | |||||||
|
Investment Amount ()
|
Value- Fund ()
|
S&P BSE
Healthcare () |
Nifty 50 ()
|
Yield (%) Fund
|
Yield (%)
S&P BSE Healthcare |
Yield (%)
Nifty 50 |
|
1 Year |
120,000 |
131,290 |
131,710 |
144,782 |
18.08 |
18.77 |
40.83 |
3 Years |
360,000 |
572,386 |
559,824 |
541,447 |
32.67 |
30.99 |
28.48 |
5 Years |
600,000 |
1,024,809 |
987,417 |
993,748 |
21.60 |
20.06 |
20.32 |
7 Years |
840,000 |
1,449,306 |
1,373,415 |
1,550,256 |
15.33 |
13.82 |
17.22 |
10 Years |
1,200,000 |
2,634,753 |
2,520,248 |
2,756,869 |
15.04 |
14.21 |
15.89 |
15 Years |
1,800,000 |
6,454,129 |
6,421,416 |
5,492,303 |
15.53 |
15.47 |
13.67 |
Since inception* |
2,030,000 |
8,459,574 |
8,549,413 |
7,436,315 |
15.16 |
15.27 |
13.88 |
Note: Systematic Investment Plan (SIP) returns are worked out assuming investment of 10,000/- every month at NAV per unit of the scheme as on the first working day for the respective time periods. The loads have not been taken into account.*Since inception for above mentioned schemes is taken for the period December 2004 to October 2021 (Since SIP facility was introduced in November 2004. Past performance may or may not be sustained in future.
*Investors should consult their Mutual Fund Distributor if in doubt about whether the product is suitable for them.
- Long term capital appreciation
- Investment predominantly in equity and equity related securities in the Healthcare Service sector
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.
